Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) Income from Continuing Operations: 2023-2025

Historic Income from Continuing Operations for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$2.0 million.

  • BioLineRx's Income from Continuing Operations rose 45.04% to -$2.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$7.7 million, marking a year-over-year increase of 80.04%. This contributed to the annual value of -$11.3 million for FY2024, which is 76.25% up from last year.
  • Latest data reveals that BioLineRx reported Income from Continuing Operations of -$2.0 million as of Q2 2025, which was down 2.84% from -$2.0 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Income from Continuing Operations ranged from a high of $54,000 in Q4 2024 and a low of -$19.5 million during Q4 2023.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$3.8 million (2024), whereas its average is -$6.3 million.
  • Data for BioLineRx's Income from Continuing Operations shows a peak YoY soared of 100.28% (in 2024) over the last 5 years.
  • Over the past 3 years, BioLineRx's Income from Continuing Operations (Quarterly) stood at -$19.5 million in 2023, then surged by 100.28% to $54,000 in 2024, then soared by 45.04% to -$2.0 million in 2025.
  • Its Income from Continuing Operations was -$2.0 million in Q2 2025, compared to -$2.0 million in Q1 2025 and $54,000 in Q4 2024.